Trial Profile
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Dulaglutide (Primary) ; Exenatide
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AWARD-1
- Sponsors Eli Lilly and Company
- 01 Apr 2022 Results of post-hoc pooled analysis of six studies (AWARD-1, -2, -3, -6, -8 and -9) assessing association between treatment with dulaglutide and glycaemic variability in adult patients with type 2 diabetes mellitus, published in the Diabetes, Obesity and Metabolism.
- 16 Jun 2020 Results of post-hoc analysis assessing GV in people with type 2 diabetes, treated with once-weekly dulaglutide (DU), and not receiving any concomitant insulin treatment presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 26 Jun 2018 Results of pooled data from 5 phase 3 trial, were presented at the 78th Annual Scientific Sessions of the American Diabetes Association.